Bull Of The Day: Biogen
Zacks Investment Research
•
Fri, Jun 14
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
3,658 people get BIIB articles and Market Currents by email alert.
Get email alerts on BIIB »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Tecfidera Raises The Bar For Biogen IdecBrian L. Wilson • Mon, Apr 1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Biogen: A 'Decimated' Pipeline?Derek Lowe • Tue, Jan 17, 2012
-
Biogen Idec Inc. - Shareholder/Analyst CallWed, Jun 12
-
Biogen Idec's CEO Hosts 2012 Analyst Day (Transcript)Tue, Jun 12, 2012 • 1 Comment
-
Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Jan 31, 2012
-
Biogen Idec's CEO Discusses Q3 2011 Results - Earnings Call TranscriptFri, Oct 28, 2011
-
Biogen Idec Inc. - Special CallWed, Oct 26, 2011
-
Biogen Idec's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Jul 26, 2011
-
Biogen Idec's CEO Discusses Q1 2011 Results - Earnings Call TranscriptThu, Apr 21, 2011
-
Biogen Idec CEO Discusses Q3 2010 Results - Earnings Call TranscriptTue, Oct 26, 2010
-
Biogen Idec Inc. Q2 2010 Earnings Call TranscriptTue, Jul 20, 2010
-
Biogen Idec, Inc. Q1 2010 Earnings Call TranscriptTue, Apr 20, 2010
-
Biogen Idec, Inc. Q4 2009 Earnings Call TranscriptTue, Feb 9, 2010 • 1 Comment
-
Biogen Idec Inc. Q3 2009 Earnings Call TranscriptTue, Oct 20, 2009
-
at MarketWatch.com (Wed, 4:10PM)
-
Business Wire (Jun 4, 2013)
-
at CNBC.com (Jun 3, 2013)
-
at MarketWatch.com (Jun 3, 2013)
-
Business Wire (May 29, 2013)
-
Business Wire (May 28, 2013)
-
Business Wire (May 23, 2013)
-
Business Wire (May 22, 2013)
-
Business Wire (May 21, 2013)
-
at CNBC.com (May 14, 2013)
-
Business Wire (May 13, 2013)
-
at CNBC.com (May 9, 2013)
-
at MarketWatch.com (May 9, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at MarketWatch.com (Apr 26, 2013)
-
at CNBC.com (Apr 25, 2013)
-
at MarketWatch.com (Apr 25, 2013)
-
Business Wire (Apr 25, 2013)
-
at CNBC.com (Apr 24, 2013)
BIIB vs. ETF Alternatives
Company Description
Biogen Idec is a global biotechnology company that creates new standards of care in therapeutic areas with high unmet medical needs. Our business strategy is focused on discovering and developing first-in-class or best-in-class products that we can deliver to specialty markets globally.... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, April 25, 7:47 AM More on Biogen's (BIIB) Q1: Revenue gains driven by 13% Y/Y growth of AVONEX. RITUXAN revenues reduced by $42M for damages awarded to Genentech. FAMPRYA and FUMADERM sales up 25%. Corporate partner revenues were $22M versus $3M in the comparable period last year. FY2013 guidance: revenue growth of between 16-18% and non-GAAP EPS of between $7.80-7.90. Analysts expect EPS of $7.79. Shares +2.8% premarket. (PR) Comment! [Healthcare, Earnings, On the Move]
- Thursday, April 25, 6:31 AM Biogen Idec (BIIB): Q1 EPS of $1.97 beats by $0.36. Revenue of $1.4B (+10% Y/Y) misses by $0.01B. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
- Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
- Monday, January 28, 11:07 AM Biogen Idec (BIIB +2.8%) on a mixed Q4 report, missing on its bottom line but slightly beating on revenue. Net earnings actually fell 2.7% Y/Y, due largely to the company's preparations to launch its new multiple sclerosis drug BG-12, which masked revenue growth from its existing MS treatment. The company also boosted its FY13 revenue growth expectations to 10%. Analysts are looking for a 9% rise to $5.98B. 1 Comment [Healthcare, On the Move, Earnings]
- Monday, January 28, 6:33 AM Biogen Idec (BIIB): Q4 EPS of $1.40 misses by $0.06. Revenue of $1.42B (+7% Y/Y) beats by $30M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, January 28, 12:05 AM Notable earnings before Monday’s open: BIIB, CAT, NTE Comment! [Earnings]
- Sunday, January 27, 5:30 PM Notable earnings before Monday’s open: BIIB, CAT, NTE Comment! [Earnings]
- Thursday, October 25, 2012, 7:18 AM Biogen Idec (BIIB): Q3 EPS of $1.91 beats by $0.32. Revenue of $1.4B (+6% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Thursday, October 25, 2012, 12:05 AM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH Comment! [Earnings]
- Wednesday, October 24, 2012, 5:30 PM Notable earnings before Thursday’s open: ABB, AET, AUO, AVT, AZN, BEN, BG, BIIB, CAB, CCE, CELG, CL, CME, CMS, CNX, COP, CRR, CS, CVE, D, DBD, DDD, DNKN, EQT, GG, GTI, HERO, HOT, HSY, IMAX, IP, JBLU, JNS, LINE, LKQ, MCK, MJN, MO, MYL, NBL, NOV, NS, NVS, NXPI, NYT, O, ORI, OXY, PCAR, PCP, PDS, PG, PHM, POT, PTEN, RCL, ROC, RTN, RYN, S, SHW, SPG, SWI, TKR, TSM, TZOO, UA, UAL, VLY, VPHM, XEL, ZMH 1 Comment [Earnings]
- Tuesday, July 24, 2012, 12:36 PM More on Biogen (BIIB) Q2: net profit +34% to $386.8M, helped by strong sales of multiple-sclerosis treatment Avonex and cancer drug Rituxan, and reflecting a $50M charge last year. Ups FY EPS guidance to $6.20 from $6.15 prior, vs. consensus of 6.22. Shares flat at $139.28, although they had been as high as $142.68. BIIB had gained 27% YTD through yesterday. Comment! [Earnings, Healthcare]
- Tuesday, July 24, 2012, 7:07 AM Biogen Idec (BIIB): Q2 EPS of $1.82 beats by $0.26. Revenue of $1.4B (+18% Y/Y) beats by $70M. (PR) Comment! [Earnings, Healthcare]
- Tuesday, July 24, 2012, 12:05 AM Notable earnings before Tuesday’s open: AME, APD, BIIB, BTU, CNC, COL, DD, DLPH, EMC, GNTX, ITW, LMT, LXK, MO, NXPI, PCAR, RAI, RF, SAP, SNV, SPG, T, UA, UPS, VMED, WHR, WU Comment! [Earnings]
- Monday, July 23, 2012, 5:30 PM Notable earnings before Tuesday’s open: AME, APD, BIIB, BTU, CNC, COL, DD, DLPH, EMC, GNTX, ITW, LMT, LXK, MO, NXPI, PCAR, RAI, RF, SAP, SNV, SPG, T, UA, UPS, VMED, WHR, WU 1 Comment [Earnings]
- Tuesday, May 1, 2012, 12:37 PM Biogen (BIIB) -0.8% following its Q1 miss, which was due to weaker-than-expected sales of its Avonex multiple sclerosis drug. Still, net profit edged up 3% to $302.7M. Biogen upgraded its 2012 outlook, and it now expects adjusted EPS of over $6.15 and revenue growth in the mid-single digits. Comment! [Earnings, Healthcare]
-
Kenneth Hackel
Last week CT Capital sold $BIIB after tripling and bought #QCOR at $30.96, up 30% in a week. - View all 0 replies
-
Ryan Mallory
Fuinhaz Setups for April 25 2013 | $AKAM $ALNX $BIIB $CROX $INFN $LSI $PERI $YNDX | SharePlanner http://bit.ly/12Kc6ip - View all 0 replies
-
- View all 1 replies
-
-
Jim Van Meerten
$BIIB - 96% Barchart technical buy signals - 11 new highs and up 15.13% in the last month - Relative Strength Index 78.77% - View all 0 replies
-
Michael Bryant
Biogen Idec ($BIIB) is surging higher. Still more bight days ahead for the biotech giant. http://yhoo.it/XWT1oi;c= - View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
Jim Van Meerten
$BIIB - 96% Barchart technical buy signal - 11 new highs and up 8.90% in the last month - Relative Strength Index 70.31% - View all 0 replies
-
Tony Kau
$BIIB exhausted - good credit spread play: Apr 190/195 calls for $0.80; expected return: 11%! http://ow.ly/i/1GyN8 http://ow.ly/iVHJ3 - View all 2 replies
-
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Tony Kau
$BIIB exhausted - good credit spread play: Apr 190/195 calls for $0.80; expected return: 11%! http://ow.ly/i/1GyN8 http://ow.ly/iVHJ3 - View all 2 replies
-
-
-
- View all 3 replies
-
FortSumter: an appointment in the Obama administration. Renewal, that is. Thanks for the list. -
-
- View all 3 replies
-
-
-
- View all 5 replies
-
-
-
- View all 4 replies
-
Iron Hamster: Any idea why SCL is dropping? Everything I'm reading says it's a buy and it's too early for profit taking, yet it's down on an up day. -
-
- View all 1 replies
-
-
- View all 1 replies
-
-
Justin M. Hall
8/6/11 12A ET: (VRUS, ALXN, BIIB, ILMN, PRGO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg - View all 1 replies
-
-
- View all 1 replies
-
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.